@prefix this: . @prefix sub: . @prefix np: . @prefix pav: . @prefix rdf: . @prefix infores: . @prefix xsd: . @prefix umls: . @prefix orcid: . @prefix rdfs: . @prefix biolink: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubInfo; a np:Nanopublication . } sub:assertion { a biolink:ChemicalEntity; rdfs:label "Vericiguat"; biolink:category biolink:ChemicalEntity . umls:C4707345 a biolink:DiseaseOrPhenotypicFeature; rdfs:label "cardiovascular death"; biolink:category biolink:DiseaseOrPhenotypicFeature . a biolink:DiseaseOrPhenotypicFeature; rdfs:label "heart failure"; biolink:category biolink:DiseaseOrPhenotypicFeature . sub:_1 rdf:object ; rdf:predicate biolink:treats; rdf:subject ; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications . sub:_2 rdf:object umls:C4707345; rdf:predicate biolink:treats; rdf:subject ; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications . } sub:provenance { sub:assertion prov:generatedAtTime "2022-10-13T12:49:16.653528"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-3668-2627; prov:wasQuotedFrom " Vericiguat is indicated in adults with symptomatic, chronic heart failure and an ejection fraction of <45%. It is indicated to reduce the risk of cardiovascular death and heart failure-related hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics. It reduces cardiovascular death, heart failure related hospitalization, and hospitalization associated with heart failure." . biolink: pav:version "2.3.0" . } sub:pubInfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEApdULbl+/+pkVlq0fAzWmzfgIb+XMuQPKHMDVzUTWCZBjLfzORll42ptr52e4w7tTYkUKrBsQbx8lkjZWAlWiyh+xIK0oLFSdYRSt63kgiyRYBUOR+spcgmofb7f6JyftArPVTKhsWOMt/mcyNG9qc3lw8B/xuPmLteUWO33xWhfXQreTw1lsGUkZ1j4cB4X9HIuI20ktLYLCXaBauNHEJZ4qp6/Q2ATsJcw8tg7aRmFKXhrjM9maZ2+0cMg0Jpmn2UnDlPKXEA6Qq+qnvvQt8KFjIzP9FTMyvrWl8tTd0NCmS9VpooZJQ8We1lGMPXg5bMbe/bVkTf70fbFMf0RKrQIDAQAB"; npx:hasSignature "NeM7mkjXRerJBlvIcY0zMJKN4BAXVWb3IpLHBpiGDmj9bNewdqtscO79XJaBYOVpp+jbhv6N/LC7jEIxRGhG1pGRZJ9o5AIGOEZi2LYCLZcczXhN5IuaW3l53CkFfdewodhZy/OSyt9G9ldvoSjBMN5IsV+b6Yr22/GuY9CDOy+qslnLgXJgY886Rry6pdPIJ7iykNRbzona6nuRM/hiZjcw7OxXCQ8x4C5+eA+p7gFzTA1HIegDQhY3O3X3eUeIqVFTsBaxTn6LYcLrL5EV1wuwuQAItNqxb00t5frA3ba+4eJPZrpVMqNTNMgl3VHrviX8unOTCfb7g+qLnE1sZw=="; npx:hasSignatureTarget this: . this: prov:generatedAtTime "2022-10-13T12:49:16.653528"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-3668-2627 . }